USPTO serial 97748253
NIPPON CHEMIPHAR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 1, 2024
- Examiner
- GAGNER, NICHOLAS M
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NIPPON CHEMIPHAR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mary Margaret L. O'Donnell
Mary Margaret L. O'Donnell Blue Filament Law PLLC772 E. Maple RoadBirmingham, MI 48009United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic reagents for medical research; Diagnostic reagent kits consisting of chemical reagents, cell culture reagents, biochemical reagents for medical research | ACTIVE | — |
| 005 | Pharmaceutical preparations for Cardiovascular Disorders, Genitourinary Disorders, Gynecological diseases, Cancer and cancer supportive care, Eye Disorders, Neurologic Disorders, Psychiatric Disorders, Endocrine and Metabolic Disorders, Allergic Disorders, Gastrointestinal Disorders, Immune Diseases and Autoimmune Diseases, Respiratory Diseases, Musculoskeletal and Connective Tissue Disorders, Infectious Diseases, Dermatologic Disorders, Hematological Disorder, Inflammatory Diseases, Ear, Nose, Dental and Throat Disorders, Hepatic and Biliary Disorders, Kidney Diseases, Medicines for improving sleep, Medicines for controlling sickness from drinking, Medicines for controlling hangovers; Obstetric medicines being medical preparations for the treatment of endometriosis or adenomyosis; local, topical, general, inhalant anesthetic; Sedatives; Analgesic drugs; Alkalinizing agents being preparations for the lowering pH levels in patients; Anti-aging agents being pharmaceutical preparations for reducing the effects of aging in patients; reagent paper for medical purposes; pharmaceutical preparations for reducing pain, reducing inflammation; pharmaceutical preparations and substances with antipyretic properties anti-inflammatories and analgesic properties for the treatment of nociceptive pains, the treatment of neuropathic pains, the treatment of visceral pains, the treatment of rheumatoid arthritis, the treatment of low back pain, and the treatment of after surgery, trauma, and tooth extraction; pharmaceutical preparations for the treatment of gout and hyperuricemia; Pharmaceutical preparations for treating hypertension; pharmaceutical preparations and substances for the treatment of cancer; Hygiene agent, namely, medical cleanser for skin and wounds; Eye patches and skin patches for medical purposes, namely, pharmaceutical preparations for reducing pain, reducing inflammation; medicated ointments for treating dermatological conditions; Infusion drug for medical purposes, namely, pharmaceutical preparations for reducing pain, reducing inflammation that need to be administered gradually intravenously; Diagnostic agents and reagents for medical use; diagnostic reagents for medical purposes; Medical diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; In vitro diagnostic reagent for medical use; In vitro diagnostic reagents kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in determining allergies; medical oiled paper; Drug delivery agents in the form of wafers for wrapping powdered pharmaceuticals for medicine doses; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages spray; Breast-nursing pads; cotton swabs for medical use; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; Vitamin fortified beverages for babies for medical purposes; food for babies; dietary-supplements-for-animals other than drugs; Semen for artificial insemination; ferments for pharmaceutical purposes; Food supplements, namely, antioxidant pills; dietary supplements for anti-aging immune system for humans; appetite suppressant pills; dietary fiber to aid digestion; pharmaceutical preparations for treating dry skin; Pharmaceutical preparations being medical application cream pharmaceuticals for treating skin conditions; pharmaceutical preparations for skin care; Nasal sprays for medical purposes | ACTIVE | — |
| 010 | Medical apparatus and instruments, namely, medical devices for use in diagnosing allergies; Medical diagnostic apparatus and instruments for diagnostic for immunotherapy medical purposes; Medical diagnostic apparatus and instruments, namely, medical devices for use in diagnosing allergies; apparatus for use in medical purpose for identifying allergens causing allergy, namely, medical devices for use in diagnosing allergies; medical diagnostic apparatus for testing and quantifying the amount of allergen-specific antibody; Genetic testing apparatus for medical purposes; medical measuring apparatus, namely, medical apparatus for measuring skin hydration; Medical diagnostic apparatus for measuring, testing and analyzing specimens reacted with diagnostic reagents; medical diagnostic apparatus, namely, immunoassay analyzer being medical diagnostic apparatus for testing for viruses; mobile medical apparatus for enzyme-linked immunosorbent assay, namely, medical diagnostic apparatus for testing for blood protein, DNA for allergy screening; medical diagnostic apparatus for testing and measuring specific immunoglobulin E (IgE) antibodies; Sanitary masks for personal use; dental materials being dental implants | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nippon Chemiphar Co., Ltd.
- Other trademarks owned by Nippon Chemiphar Co., Ltd.
- Other trademarks owned by Nippon Chemiphar Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named NIPPON CHEMIPHAR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 13, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 13, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 13, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 13, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 1, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 1, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 16, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 16, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 26, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 30, 2024 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| May 28, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 23, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 23, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 23, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 23, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 22, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 22, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 22, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 22, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 23, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 23, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 23, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 5, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 4, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 4, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 5, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 3, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 31, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 13, 2023 | NWAP | NEW APPLICATION ENTERED | — |